#Anthony Fauci, MD

Federal researchers describe two paths to a vaccine—and one of them uses high-tech computers to design a vaccine candidate!

The CDC holds the patents to Truvada-as-PrEP, but hasn’t asked for a dime in royalties from Gilead. This is costing taxpayers billions. Why?

Broad details emerge, such as targeting the HIV hot spots that, when combined, account for 50 percent of new HIV cases.

The new federal initiative will work with existing research programs in eight cities.

The newly released PARTNER2 study documented 77,000 condomless anal sex acts between mixed-HIV-status men; Opposites Attract had 12,000.

Promising news on the prevention front

At stake in amfAR’s civil war is the nonprofit’s quest to find a cure for HIV.

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

A statement from the National Institutes of Health on World AIDS Day 2017.

Although we have the tools to end the epidemic through treatment and PrEP, costs and other considerations limit these methods.

A 9-year-old South African child infected with HIV at birth has been in an apparent state of extended viral remission.

HIV scientists and advocates are waging a powerful war against the global epidemic.

See a “POZ on Location” video with highlights from the United States Conference on AIDS and scroll through 15 tweets from HIV advocates.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

The vaccine prompted a robust immune response against HIV in those without the virus; now researchers hope to move it into advanced trials.

The child was treated with antiretrovirals for only 40 weeks starting at 9 weeks of age and has since maintained a fully suppressed virus.